In the Phase III trial, the combination of Padcev and Keytruda improved event-free survival and overall survival in MIBC.

Novartis' mAb ianalumab helped maintain safe platelet levels for a prolonged period, reducing patient reliance on hospital trips.

The FDA has given the green light for Tiziana Life Sciences’ IND to advance its Phase IIa study of intranasal foralumab for MSA.

Stoke Therapeutics and Biogen have dosed the first subject in the Phase III EMPEROR trial of zorevunersen for Dravet syndrome treatment.